

ECULIZUMAB (SOLIRIS®) PRESCRIBER ORDER FORM

Patient Name: _____	Date of Birth: _____	Gender: _____
----------------------------	-----------------------------	----------------------

Address: _____

Phone: _____	Height:	<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight:	<input type="checkbox"/> lbs <input type="checkbox"/> kg
---------------------	----------------	---	----------------	--

Clinical Information

Primary Diagnosis Description: _____	ICD-10 Code: _____
---	---------------------------

Meningococcal Vaccination Status:	<input type="checkbox"/> Primary vaccination series completed – date: _____ <input type="checkbox"/> MenACWY booster completed – date: _____ <input type="checkbox"/> MenB booster completed – date: _____
--	--

Ecuzumab (Soliris®) Prescription**Ecuzumab (Soliris®) refill as directed x 1 year**

Induction Dose: Infuse 600 mg IV over at least 35 min weekly x 4 weeks.
 Infuse 900 mg IV over at least 35 min weekly x 4 weeks.
 Other: _____

Maintenance Dose: Infuse 900 mg IV over at least 35 min on Week 5, then every 2 weeks thereafter.
 Infuse 1200 mg IV over at least 35 min on Week 5, then every 2 weeks thereafter.
 Infuse _____ mg IV over at least 35 min every 2 weeks.
 Other: _____

Max infusion time not to exceed 2 hours.

Ancillary Orders**Anaphylaxis Kit**

If this is a first dose, does this patient require an anaphylaxis kit?

 Yes, with 1st dose Yes, with all doses

Dosage: • Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SUBQ or IM x 1; repeat x 1 in 5 to 15 min PRN.
• Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement.
• 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis.

Medication Orders
 Acetaminophen 650 mg PO 30 min before infusion. Patient may decline.
 Diphenhydramine 25 mg PO 30 min before infusion. Patient may decline.
 Other: _____
IV Flush Orders
 Peripheral: 0.9% Sodium Chloride 2 to 3 mL pre-/post-use.
 Implanted Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.
Lab Orders
 No labs ordered at this time.
 Other: _____

Skilled nurse to assess and administer and/or teach self-administration, where appropriate, via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year.

If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.

I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.

Prescriber Signature: _____	Date: _____
------------------------------------	--------------------

Prescriber Information

Prescriber Name: _____	Phone: _____	Fax: _____
Address: _____	NPI: _____	
City, State: _____	Zip: _____	Office Contact: _____

Fax completed form, insurance information, and clinical documentation to: 713-983-4647

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING:** This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.

Not valid for use for patients residing in Arizona, New York, and Wisconsin